Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: J Cardiovasc Pharmacol. 2014 May;63(5):406–411. doi: 10.1097/FJC.0000000000000061

Figure 4.

Figure 4

The cartoon depicts IL-15 mediated activation of the PI3K/ERK1/2 and JAK1/STAT3 pathways. The addition of wortmannin inhibits the activation of PI3K and the addition of WP1066 inhibits the activation of STAT3. Note that the binding affinity of IL-15 to each receptor is unknown.